AHL Partners LLP grew its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 156.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,267 shares of the medical research company’s stock after purchasing an additional 45,351 shares during the quarter. AHL Partners LLP’s holdings in Agilent Technologies were worth $4,405,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Sun Life Financial INC raised its holdings in Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after purchasing an additional 2,353 shares in the last quarter. Acrospire Investment Management LLC raised its holdings in Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after purchasing an additional 1,200 shares in the last quarter. Parallel Advisors LLC raised its holdings in Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after purchasing an additional 131 shares in the last quarter. Trust Co. of Vermont raised its holdings in Agilent Technologies by 1.8% in the second quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock worth $166,000 after purchasing an additional 50 shares in the last quarter. Finally, Fiduciary Trust Co. bought a new position in Agilent Technologies in the second quarter worth about $186,000.
A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 12th. Janney Montgomery Scott boosted their price target on Agilent Technologies from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, August 16th. J P Morgan Chase & Co restated an “overweight” rating and set a $70.00 price target on shares of Agilent Technologies in a research note on Wednesday, August 16th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $68.00 price target on shares of Agilent Technologies in a research note on Tuesday, September 26th. Finally, Bank of America Corporation boosted their price target on Agilent Technologies from $66.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 16th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Agilent Technologies has a consensus rating of “Buy” and an average price target of $65.12.
Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the company earned $0.49 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 25th. Shareholders of record on Tuesday, October 3rd will be issued a dividend of $0.132 per share. The ex-dividend date of this dividend is Monday, October 2nd. This represents a $0.53 annualized dividend and a yield of 0.80%. Agilent Technologies’s dividend payout ratio (DPR) is currently 27.32%.
In other news, CEO Michael R. Mcmullen sold 16,492 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $65.33, for a total value of $1,077,422.36. Following the sale, the chief executive officer now directly owns 211,872 shares of the company’s stock, valued at $13,841,597.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Didier Hirsch sold 1,200 shares of Agilent Technologies stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $66.00, for a total value of $79,200.00. Following the sale, the chief financial officer now directly owns 164,202 shares in the company, valued at $10,837,332. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 165,720 shares of company stock worth $10,488,739.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with our FREE daily email newsletter.